Cardiovascular

September 16th 2023

Even though committee members voted in support of Onpattro for patients with cardiomyopathy related to transthyretin-mediated amyloidosis, there were questions about whether it provided a clinically meaningful benefit. The FDA set an action date of Oct. 8, 2023.

June 20th 2023

Lodoco targets the inflammation that is an underlying cause of atherosclerotic cardiovascular disease. It will be available in the second half of 2023.

June 6th 2023

In an analysis, researchers determined that Inpefa is cost-effective at commonly accepted willingness-to-pay thresholds in treating patients with heart failure who have diabetes.

May 30th 2023

Inpefa (sotagliflozin) is in the SGLT inhibitor class recommended as first-line treatment for heart failure by the American Heart Association and other groups. Jardiance (empaglifozin), a competitor in that class, has a list price of $570.48 for a month's supply.